Minerva Neurosciences
NERV
87 hedge funds and large institutions have $239M invested in Minerva Neurosciences in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 32 reducing their positions, and 9 closing their positions.
46% more capital invested
Capital invested by funds: $163M → $239M (+$75.4M)
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
4.58% more ownership
Funds ownership: 74.3% → 78.88% (+4.6%)
2% more funds holding
Funds holding: 85 → 87 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 32
34% less call options, than puts
Call options by funds: $226K | Put options by funds: $340K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$13.2M |
| 2 |
AG
Artal Group
Luxembourg
|
+$7.08M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.15M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
+$764K |
| 5 |
State Street
Boston,
Massachusetts
|
+$431K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$4.16M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.39M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.03M |
| 4 |
Millennium Management
New York
|
-$951K |
| 5 |
D.E. Shaw & Co
New York
|
-$452K |
NERV Hedge Fund Activity: Q3 2019 in Review
87 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q3 2019, worth a combined $239M — up 46% from $163M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NERV positions and 9 closed out — a net gain of 3 holders — while 24 added to existing stakes and 32 trimmed.
The largest buyer was Federated Hermes, adding an estimated $13.2M. The largest seller was GMT Capital, cutting an estimated $4.16M.
- 87 institutional investors held Minerva Neurosciences (NERV) as of Q3 2019, up from 85 in Q2 2019.
- Funds reported $239M of Minerva Neurosciences stock for Q3 2019, up 46% quarter-over-quarter.
- 12 funds opened new Minerva Neurosciences positions in Q3 2019 and 9 closed out, a net change of +3 holders.
- The largest Minerva Neurosciences buyer in Q3 2019 was Federated Hermes, an estimated $13.2M added.
- The largest Minerva Neurosciences seller in Q3 2019 was GMT Capital, an estimated $4.16M sold.
Based on aggregated 13F filings for Q3 2019.